Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross J. Baldessarini, D.Sc., M.D.

Co-Author

This page shows the publications co-authored by Ross Baldessarini and Bruce Cohen.
Connection Strength

1.032
  1. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 1993 Sep; 9(2):117-24.
    View in: PubMed
    Score: 0.141
  2. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl. 1992 May; (17):12-6.
    View in: PubMed
    Score: 0.129
  3. Atypical neuroleptics, dose-response relationships, and treatment-resistant psychosis. Arch Gen Psychiatry. 1989 Apr; 46(4):381-3.
    View in: PubMed
    Score: 0.104
  4. Persistence of haloperidol in the brain. Arch Gen Psychiatry. 1988 Sep; 45(9):879-80.
    View in: PubMed
    Score: 0.100
  5. Regulation of psychiatric practice. Am J Psychiatry. 1986 Jun; 143(6):750-1.
    View in: PubMed
    Score: 0.085
  6. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry. 1985 Apr; 142(4):489-90.
    View in: PubMed
    Score: 0.079
  7. Haloperidol levels and clinical response. Am J Psychiatry. 1981 Nov; 138(11):1513-4.
    View in: PubMed
    Score: 0.062
  8. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000 Sep 15; 48(6):467-76.
    View in: PubMed
    Score: 0.058
  9. Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology. 1980 Jul; 19(7):663-8.
    View in: PubMed
    Score: 0.057
  10. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000 Feb; 157(2):220-8.
    View in: PubMed
    Score: 0.055
  11. Clinical dosing of neuroleptics. Psychopharmacol Ser. 1993; 10:138-48.
    View in: PubMed
    Score: 0.034
  12. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl). 1992; 108(3):338-44.
    View in: PubMed
    Score: 0.031
  13. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988 Jan; 45(1):79-91.
    View in: PubMed
    Score: 0.024
  14. Binding of [3H]apomorphine to an aporphine binding site as well as to dopamine sites in tissue from bovine caudate nucleus. Neuropharmacology. 1984 Aug; 23(8):885-92.
    View in: PubMed
    Score: 0.019
  15. Circadian changes in the destruction and effects of haloperidol in the rat. Neuropharmacology. 1982 Jul; 21(7):663-9.
    View in: PubMed
    Score: 0.016
  16. Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sci. 1980 Aug 25; 27(8):633-40.
    View in: PubMed
    Score: 0.014
  17. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry. 1989 Oct; 146(10):1289-92.
    View in: PubMed
    Score: 0.007
  18. Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry. 1988 Dec; 145(12):1552-6.
    View in: PubMed
    Score: 0.006
  19. Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. Neuropharmacology. 1988 Nov; 27(11):1117-24.
    View in: PubMed
    Score: 0.006
  20. Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984 May 11; 307(2):457-63.
    View in: PubMed
    Score: 0.005
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.